|
Pharmaceutical Pricing, Reimbursement, and Prescribing News in the First Quarter of 2005Published by: Decision Resources Published: Jun. 30, 2005 The price of this report has been reduced due to its age. The original price was $1,900 for PDF E-mail From Publisher.Table of Contents
AbstractThe first quarter of 2005 was relatively quiet in the pricing, reimbursement, and prescribing environments of the world's major pharmaceutical markets. The United States continued the implementation of the Medicare Modernization Act; the act's new prescription drug benefit is expected to give a substantial boost to pharmaceutical sales. At the same time, some members of Congress, state governments, and large employers pursued measures to reduce prescription drug prices in the United States. Several leading pharmaceutical companies responded to growing criticism of their prices by launching a new drug discount card. In Europe, governments sought ways to refine their well-established cost-containment strategies. Reference pricing provoked controversy in France and Germany, and the relatively underdeveloped generics markets of Southern Europe continued to grow. In Japan, industry observers saw signs of increasing pressure for reform of the pricing and reimbursement system.Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||